Современные представления о контраст-индуцированном остром почечном повреждении: Взгляд интервенционного радиолога

Результат исследований: Научные публикации в периодических изданияхОбзорная статьянаучнаярецензирование

Выдержка

Clinically relevant contrast-induced acute kidney injury (CI-AKI) is a severe complication of
interventional contrast-based procedures of all kinds. It is linked to high morbidity, mortality, social and
fi nancial losses. Acute renal damage after coronary angiography or percutaneous coronary intervention
may occur in 1-2% cases in general population or in more than 50% of cases with high risk of developing
CI-AKI. It is very important to identify existing compromised renal function in a high-risk patient, as it is
a major and frequent CI-AKI predisposing factor. There are novel biomarkers with rapid or nearly instant
response to acute subclinical contrast-induced renal damage, which are highly valuable in CI-AKI diagnosis
and for this reason desire deeper clinical research. Despite a number of controversies, prophylactic and
therapeutic measures are practically the same in a vast majority of guidelines. Intravenous 0.9% NaCl
solution remains one and only proved measure in CI-AKI prophylaxis and therapy, while the use of other
pharmacological approaches still needs more relevant prospective clinical research. The aim of this paper
was review contemporary, CI-AKI-devoted, evidence-based data.
Переведенное названиеContemporary review of contrast-induced acute kidney injury: An interventional radiologist notion
Языкрусский
Страницы407-417
Число страниц10
ЖурналНЕФРОЛОГИЯ И ДИАЛИЗ
Том19
Номер выпуска3
СостояниеОпубликовано - окт 2017

Ключевые слова

    Цитировать

    @article{482cbdda954348859f6526164a51153f,
    title = "Современные представления о контраст-индуцированном остром почечном повреждении: Взгляд интервенционного радиолога",
    abstract = "Clinically relevant contrast-induced acute kidney injury (CI-AKI) is a severe complication ofinterventional contrast-based procedures of all kinds. It is linked to high morbidity, mortality, social andfi nancial losses. Acute renal damage after coronary angiography or percutaneous coronary interventionmay occur in 1-2{\%} cases in general population or in more than 50{\%} of cases with high risk of developingCI-AKI. It is very important to identify existing compromised renal function in a high-risk patient, as it isa major and frequent CI-AKI predisposing factor. There are novel biomarkers with rapid or nearly instantresponse to acute subclinical contrast-induced renal damage, which are highly valuable in CI-AKI diagnosisand for this reason desire deeper clinical research. Despite a number of controversies, prophylactic andtherapeutic measures are practically the same in a vast majority of guidelines. Intravenous 0.9{\%} NaClsolution remains one and only proved measure in CI-AKI prophylaxis and therapy, while the use of otherpharmacological approaches still needs more relevant prospective clinical research. The aim of this paperwas review contemporary, CI-AKI-devoted, evidence-based data.",
    keywords = "нефропатия, повреждение почек, контрастные вещества, биомаркеры почечного повреждения",
    author = "Хильчук, {Антон Андреевич} and Щербак, {Сергей Григорьевич} and Сарана, {Андрей Михайлович} and Власенко, {Сергей Васильевич}",
    year = "2017",
    month = "10",
    language = "русский",
    volume = "19",
    pages = "407--417",
    journal = "НЕФРОЛОГИЯ И ДИАЛИЗ",
    issn = "1680-4422",
    number = "3",

    }

    TY - JOUR

    T1 - Современные представления о контраст-индуцированном остром почечном повреждении

    T2 - НЕФРОЛОГИЯ И ДИАЛИЗ

    AU - Хильчук, Антон Андреевич

    AU - Щербак, Сергей Григорьевич

    AU - Сарана, Андрей Михайлович

    AU - Власенко, Сергей Васильевич

    PY - 2017/10

    Y1 - 2017/10

    N2 - Clinically relevant contrast-induced acute kidney injury (CI-AKI) is a severe complication ofinterventional contrast-based procedures of all kinds. It is linked to high morbidity, mortality, social andfi nancial losses. Acute renal damage after coronary angiography or percutaneous coronary interventionmay occur in 1-2% cases in general population or in more than 50% of cases with high risk of developingCI-AKI. It is very important to identify existing compromised renal function in a high-risk patient, as it isa major and frequent CI-AKI predisposing factor. There are novel biomarkers with rapid or nearly instantresponse to acute subclinical contrast-induced renal damage, which are highly valuable in CI-AKI diagnosisand for this reason desire deeper clinical research. Despite a number of controversies, prophylactic andtherapeutic measures are practically the same in a vast majority of guidelines. Intravenous 0.9% NaClsolution remains one and only proved measure in CI-AKI prophylaxis and therapy, while the use of otherpharmacological approaches still needs more relevant prospective clinical research. The aim of this paperwas review contemporary, CI-AKI-devoted, evidence-based data.

    AB - Clinically relevant contrast-induced acute kidney injury (CI-AKI) is a severe complication ofinterventional contrast-based procedures of all kinds. It is linked to high morbidity, mortality, social andfi nancial losses. Acute renal damage after coronary angiography or percutaneous coronary interventionmay occur in 1-2% cases in general population or in more than 50% of cases with high risk of developingCI-AKI. It is very important to identify existing compromised renal function in a high-risk patient, as it isa major and frequent CI-AKI predisposing factor. There are novel biomarkers with rapid or nearly instantresponse to acute subclinical contrast-induced renal damage, which are highly valuable in CI-AKI diagnosisand for this reason desire deeper clinical research. Despite a number of controversies, prophylactic andtherapeutic measures are practically the same in a vast majority of guidelines. Intravenous 0.9% NaClsolution remains one and only proved measure in CI-AKI prophylaxis and therapy, while the use of otherpharmacological approaches still needs more relevant prospective clinical research. The aim of this paperwas review contemporary, CI-AKI-devoted, evidence-based data.

    KW - нефропатия

    KW - повреждение почек

    KW - контрастные вещества

    KW - биомаркеры почечного повреждения

    M3 - Обзорная статья

    VL - 19

    SP - 407

    EP - 417

    JO - НЕФРОЛОГИЯ И ДИАЛИЗ

    JF - НЕФРОЛОГИЯ И ДИАЛИЗ

    SN - 1680-4422

    IS - 3

    ER -